Rockefeller Capital Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
Rockefeller Capital Management's SYRE Position: Q3 2026 in Review
Rockefeller Capital Management increased its Spyre Therapeutics (SYRE) stake by 0.98% in Q3 2026, buying an estimated $44.9K and bringing the position to 47,933 shares worth $4.27M. The position accounts for 0.01% of the portfolio, ranked #1067.
Rockefeller Capital Management first reported a position in SYRE in Q3 2025 and has held it in 5 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- Rockefeller Capital Management held 47,933 shares of Spyre Therapeutics worth $4.27M as of Q3 2026.
- Rockefeller Capital Management bought 467 Spyre Therapeutics shares in Q3 2026, an estimated $44.9K.
- Spyre Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #1067 holding.
- Rockefeller Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 5 quarters since.
- 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.